v3.25.4
COLLABORATIONS AND OTHER ARRANGEMENTS (Details)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 23, 2026
USD ($)
$ / shares
Mar. 13, 2021
USD ($)
May 27, 2020
Sep. 30, 2025
USD ($)
Jan. 31, 2025
USD ($)
Jan. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
May 31, 2023
USD ($)
Aug. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2025
USD ($)
designee
shares
Dec. 31, 2025
USD ($)
designee
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2014
Feb. 28, 2025
Jan. 30, 2023
Jul. 13, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Acquired in-process research and development expenses                       $ 1,024 $ 4,663 $ 1,155        
Research and development expenses                       5,799 5,907 5,718        
Total revenues                       29,443 28,754 27,116        
Cost of goods sold                       $ 6,234 6,251 6,498        
Arcus                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Shares owned (in shares) | shares                     31.4 31.4            
Ownership percentage                               30.00%    
Global Strategic Collaboration Agreement | Arcellx, Inc                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Acquired in-process research and development expenses                         68 313        
Maximum potential future milestone payments             $ 1,500             1,500        
Payments to acquire shares                           299        
Percentage of profits earned                                 50.00%  
Global Strategic Collaboration Agreement | Arcellx, Inc | Arcellx, Inc                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Percentage of profits earned                                 50.00%  
Merck Sharp & Dohme Corp                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Percent of global and development and commercialization costs   60.00%                                
Research and development expenses                       $ 0 0 0        
Revenues recognized                       0 0 0        
Option period to license certain inhibitors (in years)   5 years                                
Merck Sharp & Dohme Corp | Oral Formulation Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Net product sales threshold   $ 2,000                                
Percent of global product revenues   65.00%                                
Merck Sharp & Dohme Corp | Injectable Formulation Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Net product sales threshold   $ 3,500                                
Percent of global product revenues   65.00%                                
Merck Sharp & Dohme Corp | Merck                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Percent of global and development and commercialization costs   40.00%                                
Arcus collaboration agreement and stock purchase agreements | Arcus                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Opt-in term (in years)     10 years                              
Arcus collaboration agreement | Arcus                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Maximum potential future milestone payments               $ 420                    
Research and development expenses                       $ 218 243 189        
Collaboration agreement, up-front fee paid               $ 35                    
Additional option fee in future years                                   $ 100
Galapagos subscription agreement | Galapagos                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Ownership percentage                 25.80%                  
Collaboration term (in years)                 10 years                  
Potential option exercise fee                 $ 150                  
Payment of tiered royalties, low-end percentage                 20.00%                  
Payment of tiered royalties, high-end percentage                 24.00%                  
Maximum ownership percentage                 29.90%                  
Shares of common stock acquired (in shares) | shares                     16.7 16.7            
Standstill restricting term (in years)                 10 years                  
Janssen pharmaceuticals                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Purchase price of goods less specified amount, maximum percentage                             30.00%      
Total revenues                       $ 1,300 1,400 1,500        
Cost of goods sold                       369 403 430        
Period subject to termination (in years)                             10 years      
Shionogi, formerly Japan Tobacco                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Total revenues                       1,600 1,800 2,200        
Cash paid                   $ 559                
Finite-lived intangible assets acquired                   $ 550                
Amortization useful life (in years)                   9 years                
Royalty expense                       112 139 167        
Arcellx, Inc | Subsequent event                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Estimated acquisition price $ 7,000                                  
Offer price (in dollars per share) | $ / shares $ 115                                  
Contingent value right (in dollars per share) | $ / shares $ 5                                  
Contingent sales amount (at least) $ 6,000                                  
Pregene Biopharma | Pregene Biopharma Agreement                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Payments to acquire in process research and development       $ 120                            
Acquired in-process research and development expenses                     $ 80              
Maximum potential future milestone payments                     $ 1,500 1,500            
LEO Pharma A/S | LEO Pharma agreement                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Payments to acquire in process research and development         $ 250                          
Maximum potential future milestone payments         $ 1,500                          
Abingworth, LLP                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Maximum potential future milestone payments             84             $ 84        
Funding expenses                       $ 62 $ 78          
Abingworth, LLP | Maximum                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Funding received             $ 210                      
Arcus                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Option fee           $ 100                        
Number of designees on board of directors | designee                     3 3            
Additional equity investment           320                        
Arcus | Nonoperating Income (Expense)                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Additional equity investment, premium           87                        
Arcus | Prepaid and other current assets:                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Additional equity investment           $ 233                        
Galapagos                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Number of designees on board of directors | designee                     2 2